The list of companies and groups that are suing the US government over its Medicare price-setting policies continues to grow.
AstraZeneca (LSE: AZN) has now joined Merck & Co (NYSE: MRK), Bristol Myers Squibb (NYSE: BMY), Johnson & Johnson (NYSE: JNJ), the Pharmaceutical Research and Manufacturers of America (PhRMA) and others that have launched legal challenges to the drug pricing provisions of the Inflation Reduction Act (IRA).
The Anglo-Swedish pharma company says that it is taking this action to help protect access to medicines for cancer and rare disease patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze